Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

TOKYO, Nov 24, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be […]

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that the “all-case study” specified post-marketing observational study condition required at the time of approval of antiepileptic agent Inovelon Tablets 100 mg and 200 mg (rufinamide) […]

Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

EQS Newswire / 12/10/2022 / 07:15 EST/EDT Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022 CAMBRIDGE, MA […]

Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October […]

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 (Osemitamab), a humanized ADCC-enhanced anti-Claudin18.2 […]

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

LAUSANNE, Switzerland, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 […]

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

TOKYO, Sep 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. […]

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial

TOKYO and RAHWAY, N.J., Aug 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the […]

Lemon Healthcare Uses Blockchain Technology to Improve the Smart Healthcare Ecosystem for Patients

Seoul, Korea,June8, 2022- (SEAPRWire) – Lemon Healthcare, a customized service platform, is using blockchain technology to improve the smart healthcare ecosystem for patients. The company is on a mission to create an efficient and convenient platform that allows patients to access medical records, manage appointments, and communicate with medical professionals. Additionally, the brand behind the platform […]

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

SHANGHAI, CHINA, Jun 7, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved two Phase III clinical trials […]

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

TOKYO, Jun 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). The safety and efficacy findings are […]

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022

TOKYO, May 27, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. Notable […]

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor

TOKYO, Mar 28, 2022 – (JCN Newswire via SEAPRWire.com) – Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca (Generic name: Filgotinib, “Jyseleca”), Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. In September 2020, […]

Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment

Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One […]

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

HONG KONG, Mar 14, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, the Investigational […]

LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma

TOKYO, Mar 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada)’s KEYTRUDA (generic name: pembrolizumab) has been […]

Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

TOKYO and KENILWORTH, N.J., Feb 25, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine […]

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

TOKYO, Jan 31, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA (generic name: pembrolizumab) has been approved in Taiwan for the first-line treatment of patients […]

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

TOKYO, Jan 17, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, “lenvatinib”) will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), […]

Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer’s Disease In The United States

TOKYO, Dec 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost […]